Phase IIIB, MulitCenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subject DIPSS-I or High- Risk Primary Myelofibrosis, Post- Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib Including a Sub-study with Concomitant Luspatercept for Subjects with Anemia The ?FREEDOM? trial

Brief Summary

Type:
Hematologic - Other

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03755518

Study #:
STUDY00143619

Start Date:
Sep 29, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03755518

View Complete Trial Details & Eligibility at ClinicalTrials.gov